| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 17th September 2020 | Suma Krishnan | 1,126 | Open or private sale | $47.29 | $53,248.31 |
| 17th September 2020 | Suma Krishnan | 7,437 | Open or private sale | $46.63 | $346,813.34 |
| 17th September 2020 | Suma Krishnan | 10,594 | Open or private sale | $46.09 | $488,296.53 |
| 16th September 2020 | Suma Krishnan | 9,749 | Open or private sale | $46.24 | $450,821.06 |
| 16th September 2020 | Suma Krishnan | 5,142 | Open or private sale | $46.85 | $240,895.50 |
| 15th September 2020 | Suma Krishnan | 14,435 | Open or private sale | $46.21 | $667,031.25 |
| 15th September 2020 | Suma Krishnan | 1,517 | Open or private sale | $47.15 | $71,523.21 |
| 29th June 2020 | Antony A Riley | 2,000 | Open or private purchase | $14.11 | $28,220.00 |
| 26th June 2020 | Antony A Riley | 4,700 | Open or private purchase | $14.52 | $68,225.20 |
| 15th June 2020 | Suma Krishnan | 8,652 | Open or private sale | $42.24 | $365,426.74 |
Krystal Biotech
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Krystal Biotech, Inc. engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform.
Ticker: KRYS
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1711279
Employees: 37
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
We weren't able to import Fundamental data from the SEC disclosure.
There were no Red Flags found
Fundamentals
We weren't able to import Fundamental data from the SEC disclosure.
